Check for updates





Blood 142 (2023) 6679-6680

The 65th ASH Annual Meeting Abstracts

## **ONLINE PUBLICATION ONLY**

## 652.MULTIPLE MYELOMA: CLINICAL AND EPIDEMIOLOGICAL

## A Case Review on Multiple Myeloma Patients with Military Services and Toxin Exposures

Ruobing Xiao, MD<sup>1</sup>, Pavan Parmi, PharmD<sup>2</sup>, Eran Bellin<sup>2</sup>, Lucia R. Wolgast, MD<sup>3</sup>, Parsa Mirhaji, MD<sup>2</sup>

<sup>1</sup> Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY

<sup>2</sup>Albert EInstein College of Medicine, Bronx

<sup>3</sup>Department of Pathology, Albert Einstein College of Medicine, Bronx, NY

**Background:** Multiple myeloma (MM) is a bone marrow-based, multifocal plasma cell neoplasm associated with an M-protein in serum and / or urine. Events mediating progression from the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) to MM are not clearly understand. Numerous genetic events and environmental factors appear to trigger the progression of MM. Although there have been many studies on occupational and toxin exposures as risk factors to the development of non-Hodgkin's lymphoma, there are few studies that focus on military service and toxin exposures as potential risk factors to the development and progression of MM.

**Aims:** We present a descriptive analysis of MM occurrences in cohorts of patients with military background who had potential exposure to toxic agents. This is a cohort-based study that uses combination of structured clinical information from electronic health record (EHR) and natural language processing (NLP) of all clinical notes associated with patients.

**Method:** We first identified a cohort of 2329 patients diagnosed with MM. The inclusion in this cohort was ascertained by at least one occurrence of MM diagnosis including MM in remission, plasma cell leukemia in remission, or plasma cell leukemia in relapse in a cohort of 736,707 adult patients (age > 21) with an inpatient, outpatient, telehealth, or home visit between January 2016 to January 2023 in Montefiore Medical Center, Bronx, New York. All clinical notes associated with both cohorts were processed using a custom NLP query to identify cohorts of patients with military background (e.g., military service, Veteran, Vietnam war, army or navy or air force deployment). Another custom NLP query was used to identify cohort of patients with recorded history of toxic exposure (e.g., 9/11 world trade center, Agent orange, Mustard gas, Sarin gas, pesticides, herbicides, fungicides). All queries and NLP results were reviewed by the authors to ensure extraction of relevant patients, encounters, and notes.

**Results:** Our study investigates a cohort of approximately 2329 patients admitted to Montefiore Medical Center between 2016 and 2023 with diagnosis of MM. Table 1 summarizes the cohorts of MM patients in compared to the study population (denominator) in the database. Overall we identified sixteen patients with diagnosis of MM and some record of military background (Table 1). We identified eight patients with diagnosis of MM and history of toxin exposure. Among these two groups, six patients with diagnosis of MM were noted with history of military background and toxin exposure (Table 1). We then characterize the demographic information and clinical visits at diagnosis in the myeloma patients with military backgrounds / or toxin exposures (Table 2).

**Conclusion:** Our results demonstrate disproportionately high occurrence of multiple myeloma in patients with recorded history of military exposure to toxic agents when compared to other groups (9% vs 0.1% to 0.4%) and provides a rationale for further investigations.

**Disclosures** No relevant conflicts of interest to declare.

Table 1. Summary of Multiple Myeloma Cohorts Compared to Study Populations in the Database

	Base Cohorts	Military Service	Toxin Exposure	Military / Toxin Exposure
Study Populations	736707 (100%)	19734 (3%)	1976 (0.3%)	69 (0.01%)
(denominator)				
Multiple myeloma	2329 (0.3% of 100%)	16 (0.1% of 3%)	8 (0.4% of 0.3%)	6 (9% of 0.01%)

Table 2. Myeloma Patients with Demographic Information and Toxin Exposures

Myeloma	Age/sex/race	Military	Toxin	Visit setting
patients		Services	Exposures	
Patient 1	89/ male/	yes	9/11	oncology
	Hispanic			
Patient 2	62/ male/	no	pesticides	oncology
	Hispanic			5.
Patient 3	73/ male/	yes	agent orange	oncology
	unknown	,		37
Patient 4	71/ male/	yes	Vietnam	primary care
	Hispanic		veteran	
Patient 5	71/ male/ White	yes	agent orange, 911 WTC	oncology
Patient 6	89/ male/	no	pesticides	urology
	Hispanic		• 1-42 000-00 000-00-00-00	
Patient 7	80/ male/	yes	no	primary care
	unknown	-		•
Patient 8	73/ male/ African	yes	no	oncology
	American			
Patient 9	55/ male/ White	yes	pesticides	primary care
Patient 10	84/ male/ African	yes	no	primary care
	American			
Patient 11	82/ male/ White	yes	no	oncology
Patient 12	91/ male/ White	yes	no	primary care
Patient 13	90/ male/ African	yes	no	pulmonary
	American			
Patient 14	74/ male/ African	yes	no	primary care
	American			
Patient 15	85/ male/ African	yes	no	primary care
	American			
Patient 16	76/ male/ African	yes	no	oncology
	American			
Patient 17	81/ male/	yes	no	cardiology
	Hispanic			
Patient 18	71/ male/African	yes	no	oncology
	American			

Figure 1

https://doi.org/10.1182/blood-2023-182255